GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: ASN-1733 | MET-102
Compound class:
Synthetic organic
Comment: APL-2301 is a nitroxoline derivative with broad-spectrum antibacterial activity [2]. It is being developed to target infections caused by Acinetobacter baumannii.
|
|
References |
1. Asieris Pharmaceuticals.
APL-2301, a FIC small molecule developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia. Accessed on 17/06/2025. Modified on 17/06/2025. https://asieris.com/apl-2301-a-compound-developed-by-asieris-for-the-treatment-of-acinetobacter-baumannii-infection-was-approved-for-phase-i-clinical-trials-in-australia/ |
2. He P, Huang S, Wang R, Yang Y, Yang S, Wang Y, Qi M, Li J, Liu X, Zhang X et al.. (2024)
Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition. Emerg Microbes Infect, 13 (1): 2294854. [PMID:38085067] |